Method of inhibiting HIV-1 replication by administering modified GP41 C34 peptide derivatives with enhanced pharmacological properties
The claimed invention is directed toward modified HIV-1 gp41 C-terminal heptad repeat fusion inhibitors. In particular, peptide derivatives of C-34 were prepared (e.g., FB006M) and modified with 3-maleimidoproionic acid (MPA), which allows rapid and irreversible conjugation to serum albumin at a 1:1 molar ratio. These polypeptides have an extended half-life in vivo and display potent antiviral activity against HIV-1.
1. A method of inhibiting HIV-1 viral replication in a host comprising administrating a modified HIV-1 gp41 C-peptide, wherein said peptide comprises the sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:7, or a peptide derivatized with a maleimide linking moiety selected from the group consisting of SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:14, and SEQ ID NO:15.
2. The method of claim 1 , wherein said peptide is administered in the presence of said virus.
3. The method of claim 1 or 2 , wherein the peptide or peptide derivative is administered orally, topically, intravascularly, intraarterially, intramuscularly, or subcutaneously.
4. The method of claim 1 or 2 , wherein the peptide or peptide derivative is co-administered with one or more additional HIV treatment(s).
5. The method of claim 4 , wherein the said one or more additional HIV treatment(s) comprises at least one other variant gp41 peptide.
6. The method of claim 4 , wherein the additional HIV treatment(s) is selected from the group consisting of: (a) AGENERASE; (b) COMBIVIR; (c) CRIXIVAN; (d) EMTRIVA; (e) EPIVIR; (f) FORTOVASE; (g) HIVID; (h) INVIRASE; (i) KALETRA; (j) NORVIR; (k) RESCRIPTOR; (l) RETROVIR; (m) REYATAZ; (n) SUSTIVA; (o) TRIZIVIR; (p) VIDEX EC; (q) VIDEX; (r) VIRACEPT; (s) VIRAMUNE; (t) VIREAD; (u) ZERIT; and (v) ZIAGEN.
7. The method of claim 1 or 2 , wherein the mammalian cells are human cells.
8. A method of inhibiting or reducing HIV-1 replication comprising administering a peptide conjugated to a coupling group and selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:7, or a peptide derivatized with a maleimide linking moiety and selected from SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:14, or SEQ ID NO:15 to a patient whose cells have been exposed to HIV-1, wherein said peptide derivative conjugates with a blood component of said patient, thereby extending the half-life of the peptide in said patient's blood.